Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alvogen Reshaped By A Year Of Change

Group Positioned For Future By Sale Of CEE Business And Adalvo B2B Rebranding

Executive Summary

After a year that has seen Alvogen divest its central and eastern Europe business to Zentiva and rebrand its B2B unit as Adalvo, the group has also demonstrated the resilience of its supply chain in the face of upheaval caused by the coronavirus pandemic, chairman and CEO Robert Wessman tells Generics Bulletin in the second part of an exclusive interview.

You may also be interested in...



Wessman’s Fund Aztiq Pharma Buys Up Stake In Alvogen US

With “many pipeline products coming to the market in the next two years,” Alvogen’s US operation has raised fresh capital via a share issue to Aztiq Pharma, the private equity fund led by Alvogen CEO Robert Wessman.

Alvogen’s Lotus Bags $50m Investment To Boost Access In Asia

Lotus Pharmaceuticals aims to build a stronghold in Thailand and beyond, after the Alvogen subsidiary announced a partnership with a subsidiary of Thai state-owned conglomerate PTT, which includes a $50m capital injection.

Partnerships Provide Global Foundation For Alvotech

A network of marketing deals with key players across the globe has laid the foundations for Alvotech’s biosimilars to be marketed worldwide, the company’s founder and chairman tells Generics Bulletin in an exclusive interview.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150521

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel